A recens studio edita in Acta Opera quae a gene mutationem ostendit, et vocavit M. Gastroenterology and Hepatology ATRX potest ducere ad augeri periculo pancreaticum cancer in mulieres et pancreatitis. Hic primum inventa studio marcas sexus Utilia geneticae factores ad periculum pancreaticum cancer.
The team used a preclinical model to examine the effect of ATRX mutations on the adult pancreas. They deleted the ATRX gene and then studied its effect on pancreaticum cancer, susceptibility. The team found that the deletion of the ATRX gene in women increased the susceptibility to pancreatitis-related pancreatic damage and accelerated the progression of pancreatic cancer. In hominum ATRX mutationes, non ad augendam periculo pancreaticum damnum, tardus progressum in suo actu circa pancreaticum cancer.
The team ‘s preclinical results were compared with human samples from the International Cancer Genome Alliance database, which includes whole-genome sequence analysis of 729 patients. In investigationis quadrigis deprehendi XIX% de aegris portare mutations in gene ATRX in longitudinem, inter non-coding regiones, de quo LXX% sunt feminam. Maxime cum non videntur mutationes ATRX dapibus causis in tempore suo ictu mutationes, prædicebamus ATRX afficit munus contingat fere solum in mulieribus.
Associate professor Dr. physicus Thomas, et dixit Chris Pin "pancreaticum cancer est diagnosed nimis saepe contigua vastare morbo, quae est ad provecta scaena est. Respondeo dicendum quod in aegris plerumque non existentium therapies, timeo Danaos et mediocris de aegris post diagnosis Minus est quam VI mensibus. "Pancreatitis est morbus inest quaedam inflammatio pancreas est maxime momenti de pancreatic cancer periculo factores, progressionem. Cum adhuc research opus est, apud mulieres uno die fieri potest pancreatitis et summus periculo coetus identified as et hoc gene mutationem debent esse opposita texit.
In a follow-up study, Dr. Pin will work with French researchers to study patient tuberculum samples in a new preclinical model. Their goal is to better understand the mechanism of ATRX mutations as a gender-specific risk factor. In order to develop better diagnosis and treatment methods for women carrying this mutation.
